A cardiologist has discovered a new treatment that will help ease the symptoms of a heart attack in patients who are receiving intensive care.
Cardiologist Prof John Fennelly from the Mayo Clinic’s cardiac surgery unit said it is hoped that the treatment will be used by up to 30 per cent of people who suffer from acute myocardial infarction (AMI).
Cardiologist Professor Fennello said that while it is a promising new approach, it is important to remember that it is not 100 per cent effective.
“The new drug we are testing is a compound called SRI-16, and it is known to reduce the clotting of blood,” he said.
“This drug is very small and has the ability to lower the risk of a clotting reaction.”
It is also very expensive and is used by a small number of patients.
“So if you think about it, it has the potential to have an impact on up to 20 per cent.”
If that works for 30 per% of people then we should see a significant reduction in the incidence of the complication of myocarditis.
“Dr Fennell said that if it worked as well for 40 per cent, the drugs could also be used to treat up to 50 per cent more patients.
Cardiology and heart surgery are two of the most commonly used specialties within the cardiac surgery division of the Mayo clinic.
It is a division that employs thousands of people, with about a quarter of its patients being cardiologists.
It has a reputation for being very intensive in terms of patients being treated and their care.
In recent years, the number of mycardiologists has increased dramatically, from just four in 2015 to about 200 this year.
It’s a big step for the cardiac surgeon’s career and the Mayo team believe that this will help to bring the number up to a normal level in the future.
The drug, called S-26, was tested on mice, and Prof Fennells team have now developed a test that can measure the levels of the compound in patients.
The results are expected to be published later this month.”
There is a lot of work ahead of us, but we’re hopeful it will work well.””
The drug is in the lab and we will have a better idea of how well it works in humans.”
There is a lot of work ahead of us, but we’re hopeful it will work well.
“In a statement to the ABC, the company said the results from the test are currently being analysed.”
Patients who have undergone surgery at Mayo will be informed of the results of the study, which will then be published as part of the journal Circulation,” the statement said.
Prof Fennel said that he was keen to work with Mayo and the medical community to understand how the drug could be used in patients suffering from AMI.”
I would like to work closely with Mayo to understand the drug’s safety and effectiveness in treating AMI patients and its possible use in patients at risk of AMI,” he added.”
For the most part, the medical profession is in agreement that there is not a clear-cut way to use S-25 and S-16 and that we need more research to get us to that point.
“S-26 has been developed in collaboration with a number of leading cardiovascular scientists, and we are very confident it will be successful in treating patients at high risk of ami.”
As an independent specialist, I would like Mayo to help us understand whether S-20, S-24 and S and R-26 can also be effective in the same patients.
This will give us more insight into the best way to treat patients at higher risk.
“Dr Andrew Jukes from the University of New South Wales School of Medicine said that the study is exciting.”
In the UK we have some very promising treatments for AMI, and I think that this is an exciting opportunity for us to see what’s going on in patients in Australia,” he told the ABC.”
Our studies are conducted in Australia and they look at the effect of drugs on the patient.
“That is very interesting to me and to my colleagues, because this is a new area in medicine.”
Dr Jukes said that one of the first questions to ask patients is, ‘How do you feel?’
Dr Fannells team hope that S-27 could be a treatment that is very useful to those with AMI and the drug has already been approved for the treatment of severe AMI in patients with advanced myocardium.
“What we are looking at is whether SRI16 can also help patients with AMIs in general, or whether it can also benefit those with a severe myocardiac event,” he explained.
“To be honest, I am not sure if we will be able to use the drug in patients like myself who are also at high-risk for AMIs, but it’s a very exciting area of research.”